IG-001—A non-biologic micellar paclitaxel formulation for the treatment of metastatic Breast cancer

Abstract

We have recently shown that the dissolution profile of IG-001 is very similar to that of nabpaclitaxel/Abraxane®. Once injected into the circulation, both formulations quickly dissolve into paclitaxel complexed with endogenous circulating albumin, suggesting that both formulations deliver paclitaxel to the targeted tissue via albuminmediated transport. Herein, we provide a summary report of our clinical studies in Metastatic Breast Cancer (MBC) that includes two Phase 2 studies, interim results for a Phase 3, as well as a Phase 4 post-marketing surveillance (PMS) study.